… Each received a single 4-mg oral dose of lacidipine and an intravenous infusion of 400 pug
of lacidipine over 30 min in a randomized crossover study. A comparison of the determined …

… Summary: The clinical safety of the new dihydropyridine calcium antagonist lacidipine was
assessed in 14 clinical trials, including 1,372 patients treated with lacidipine and 687 treated …

… In other specific trials, lacidipine has been shown to have a … We conclude that lacidipine
is an effective antihypertensive … Furthermore, lacidipine is able to reverse the early changes …

… These reactions occurred in 5.2 to 14.1% of patients treated with lacidipine in 14 clinical …
of adverse effects with lacidipine is dose-related: 41 % of patients receiving lacidipine 4 mg/day …

… The study was performed in the internal GSK Clinical Pharmacology Unit in Verona in
compliance with current Italian laws. All related study costs were funded by GSK Italy. …

… simvastatin and lacidipine as they share the CYP3A4 metabolic pathway and the combination
of dihydropyridines with cholesterol lowering agents seems to be clinically appropriate. …

… [8] The purpose of this review is to update the appraisal of the clinical properties of lacidipine
with important new data that have become available since the original review, especially …

… of lacidipine when prescribed with atenolol (lacidipine was no evidence that there had been
… ng ml-' vs lacidipine/atenolol 3.018 + of lacidipine upon repeated dosing with the lacidipine/ …

… to assess the relative magnitude of the pharmacological activity of calcium antagonist drugs
… multiple dosing with lacidipine in this study there was an obvious pharmacological effect at …

… Clinical Investigation and Research Unit (CIRU) to evaluate theeffects of acute andchronic
lacidipine … the contralateral arm, and then lacidipine or placebo was administered orally with …